The most common side effects of A+T therapy for hepatocellular carcinoma, i.e., immunotherapy with atilizumab + bevacizumab regimen, are anemia, neutropenia, thrombocytopenia, alopecia, constipation, peripheral neuropathy, and malaise. The main side effects involve all systems of the body as follows. 1. Blood and lymphatic system: anemia, neutropenia, thrombocytopenia, lymphocytopenia. 2. Cardiovascular system: myocarditis, hypertension, hypotension. 3. Endocrine system: abnormal thyroid function, adrenal insufficiency, pituitary gland inflammation, diabetes mellitus, hypomagnesemia, hyponatremia, ovarian failure. 4. Digestive system: nausea, vomiting, diarrhea, constipation, dysphagia, oral mucositis, colitis, pancreatitis, rectal bleeding, abnormal liver function, hepatitis. 5. Motor system: arthralgia, skeletal muscle pain, myositis, muscle weakness, back pain. 6. Immune system: hypersensitivity reactions, etc. 7. Nervous system: headache, peripheral neuropathy, dizziness, inversion of taste, Guillain-Barre syndrome, meningitis. 8. Urinary system: proteinuria, nephritis, urinary tract infection. 9. Respiratory system: cough, dyspnea, nasopharyngitis, hypoxia, dysphonia. 10. Skin: rash, pruritus, alopecia, dry skin, skin discoloration, severe adverse skin reactions. 11. Systemic symptoms: fever, malaise, loss of appetite, weight loss, peripheral edema, chills, infusion-related reactions. Side effects of A+T therapy for hepatocellular carcinoma are not limited to the above, if you are being treated with A+T regimen, you should follow up with regular regular hospital visits.